Royal Bank of Canada
ALXN

Royal Bank of Canada’s Alexion Pharmaceuticals ALXN Stock Holding History

Royal Bank of Canada’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-27,000
Closed -$3.76M – 6609
2016
Q1 		$3.76M Sell
27,000
-3,000
-10% -$440K ﹤0.01% 2002
2015
Q4 		$5.72M Buy
+30,000
New +$5.24M ﹤0.01% 1778

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Royal Bank of Canada's ALXN Position: Q3 2021 in Review

Royal Bank of Canada sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 831,958 shares — an estimated $153M sold.

Royal Bank of Canada first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $153M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Royal Bank of Canada reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Royal Bank of Canada sold 831,958 Alexion Pharmaceuticals shares in Q3 2021, an estimated $153M.
  • Royal Bank of Canada first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Royal Bank of Canada's Alexion Pharmaceuticals position peaked at $153M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Royal Bank of Canada's 13F filing for Q3 2021, filed 15 Nov 2021.